Accepted for Publication: January 16, 2014.
Published Online: March 10, 2014. doi:10.1001/jamaneurol.2014.62.
Study concept and design: Van Laere, Robberecht, Van Damme.
Acquisition of data: Van Laere, Vanhee, Verschueren, De Coster, Driesen, Robberecht, Van Damme.
Analysis and interpretation of data: Van Laere, Vanhee, De Coster, Dupont, Robberecht, Van Damme.
Drafting of the manuscript: Van Laere, Vanhee, Verschueren, De Coster, Driesen, Robberecht, Van Damme.
Critical revision of the manuscript for important intellectual content: Van Laere, Dupont, Robberecht, Van Damme.
Statistical analysis: Van Laere, Driesen, Van Damme.
Obtained funding: Robberecht.
Administrative, technical, and material support: Van Laere, Vanhee, Verschueren, Driesen.
Study supervision: Van Laere, Robberecht, Van Damme.
Conflict of Interest Disclosures: Dr Robberecht is supported through the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders. Dr Van Damme is supported by the Belgian ALS League. Drs Van Laere and Van Damme are senior clinical investigators of the Flemish Fund for Scientific Research (FWO, Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Belgium). No other disclosures were reported.
Funding/Support: This work was supported by a grant from the KU Leuven (GOA/11/014) and by the Interuniversity Attraction Poles (IUAP) program P7/16 of the Belgian Federal Science Policy Office.
Role of the Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the skilled help of the radiopharmacy team at UZ Leuven, which included Marva Bex, Tjibbe de Groot, PhD, and Kim Serdons, Pharm, PhD. They did not receive compensation for their contributions.